BioLife Solutions Inc - Asset Resilience Ratio
BioLife Solutions Inc (BLFS) has an Asset Resilience Ratio of 29.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore BioLife Solutions Inc asset portfolio for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1994–2025)
This chart shows how BioLife Solutions Inc's Asset Resilience Ratio has changed over time. See BioLife Solutions Inc (BLFS) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down BioLife Solutions Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BLFS market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $120.18 Million | 29.61% |
| Total Liquid Assets | $120.18 Million | 29.61% |
Asset Resilience Insights
- Very High Liquidity: BioLife Solutions Inc maintains exceptional liquid asset reserves at 29.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioLife Solutions Inc Industry Peers by Asset Resilience Ratio
Compare BioLife Solutions Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hubei Huaqiang High-Tech Co. Ltd. A
SHG:688151 |
Medical Instruments & Supplies | 26.12% |
|
Pegavision
TW:6491 |
Medical Instruments & Supplies | 17.14% |
|
SWS Hemodialysis Care Co. Ltd. A
SHG:688410 |
Medical Instruments & Supplies | 38.45% |
|
Caina Technology Co. Ltd.
SHE:301122 |
Medical Instruments & Supplies | 19.74% |
|
IVF Hartmann Holding AG
SW:VBSN |
Medical Instruments & Supplies | 52.05% |
|
Dentium
KO:145720 |
Medical Instruments & Supplies | 1.23% |
|
Medeon Biodesign
TWO:6499 |
Medical Instruments & Supplies | 7.38% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
Annual Asset Resilience Ratio for BioLife Solutions Inc (1994–2025)
The table below shows the annual Asset Resilience Ratio data for BioLife Solutions Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.77% | $55.89 Million | $405.88 Million | +11.47pp |
| 2024-12-31 | 2.30% | $9.20 Million | $399.49 Million | -1.64pp |
| 2023-12-31 | 3.95% | $16.29 Million | $412.71 Million | -5.66pp |
| 2022-12-31 | 9.61% | $43.26 Million | $450.23 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $552.60 Million | -- |
| 2020-12-31 | 2.50% | $5.87 Million | $234.83 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $12.14 Million | -- |
| 2016-12-31 | 20.83% | $1.65 Million | $7.93 Million | +7.48pp |
| 2015-12-31 | 13.35% | $1.65 Million | $12.37 Million | -32.69pp |
| 2014-12-31 | 46.04% | $7.40 Million | $16.07 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $3.35 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $3.17 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $1.66 Million | -- |
| 1996-12-31 | 1.82% | $110.15K | $6.04 Million | +0.63pp |
| 1995-12-31 | 1.19% | $100.31K | $8.40 Million | 0.00pp |
| 1994-12-31 | 1.19% | $100.31K | $8.40 Million | -- |
About BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, inc… Read more